HIV Clinical Trial
Official title:
Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Verified date | April 5, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Respiratory infections have a high associated morbidity and mortality, especially in
immunocompromised patients. To initiate effective treatment of respiratory infections, it is
essential that a rapid and thorough laboratory analysis of respiratory specimens be
performed, given the wide range of pulmonary pathogens that can be detected in this
population. Conventional microbiology is time-consuming and cumbersome, and the capability of
local laboratories to assess specimens for rare or unusual pathogens is often limited. This
study will evaluate if a newer technology can be effectively utilized in the identification
of a broader range of infectious agents relative to conventional procedures.
Resequencing Pathogen Microarray (RPM) technology developed by TessArae , LLC which ceased
operations in July 2014) uses a microarray chip to identify multiple pathogens in a clinical
specimen. The technology has had limited clinical application, but early studies have shown
its effectiveness in accurately identifying a large number of viral and bacterial organisms.
In contrast to conventional microbiological procedures based on phenotypic traits (growth
characteristic and enzymatic activity), this is microarray utilizes DNA sequence analysis to
detect and identify the species, serotype/subtype, or strain of the infectious agent.
Aliquots of respiratory specimens (initially, specimens collected by bronchoalveolar lavage,
BAL) from 200 patients at the NIH Clinical Center and the Washington Hospital Center will be
analyzed using the customized microarray chip. The specimens will be collected as part of the
patients routine clinical care. The results of the TessArray microarray analysis will not be
available to the clinician and therefore will not have any effect on the clinical care of the
patients.
The results of the microarray analysis from each site will be compared to that site s
clinical laboratory results, and the data will be analyzed by site.
Status | Terminated |
Enrollment | 129 |
Est. completion date | April 5, 2016 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility |
- INCLUSION CRITERIA: Subjects may be included in this study if they: 1. Are 2 years of age and older. 2. Are being evaluated for a respiratory infection. 3. Are having respiratory specimens collected as part of their clinical evaluation. 4. Agree to have specimens stored for future research. EXCLUSION CRITERIA: Patients unable or unwilling to give informed consent will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | National Institutes of Health Clinical Center (CC) |
United States,
Boyton RJ. Infectious lung complications in patients with HIV/AIDS. Curr Opin Pulm Med. 2005 May;11(3):203-7. Review. — View Citation
Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995 Sep 28;333(13):845-51. — View Citation
Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med. 2004 Mar;25(1):189-201. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The sensitivity, compared to standard microbiological methods, of a customized TessArray microarray for the diagnosis of respiratory infections. | At time of enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |